Clinical-Microbiomics, CosmosID, DNASense, and MS-Omics have merged to form Cmbio. Please visit our new site cmbio.ioVisit cmbio.io
 

Blog

bt_bb_section_bottom_section_coverage_image

The field of microbiome-based therapeutics is flourishing. The recent approval of Seres Therapeutics’ drug, Vowst, against C. difficile infections has spearheaded the interest in microbiome-based therapeutics.    The recent development of microbiome-based therapeutics may have contributed to a rising trend of reclassifying microbiome probiotics as pharmaceuticals. The European Union (EU) is witnessing significant progress in...

The gut microbiome has clear implications for health and disease. Recent evidence of this comes from a US FDA vote for approval of the microbiome-based drug RBX2660, created by Rebiotix Inc, A Ferring Company, to treat potentially deadly bacterial infections with Clostridium difficile (Cdiff). Cdiff is a common gut bacteria that may cause severe diarrhea...

Plastic particles < 5 mm are classified as microplastics. Microplastics are present in almost all aquatic ecosystems, from the Arctic to the deep ocean. Moreover, microplastics can migrate between different aquatic environments, such as lakes, seas and oceans. This environmental problem becomes a health concern when the microplastics enter into a new aquatic ecosystem where...